Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) shares rose 4.4% during mid-day trading on Friday . The stock traded as high as C$80.00 and last traded at C$80.00. Approximately 2 shares traded hands during trading, a decline of 99% from the average daily volume of 331 shares. The stock had previously closed at C$76.60.
Cosmo Pharmaceuticals Stock Performance
The company’s 50-day moving average price is C$75.03 and its 200-day moving average price is C$61.13.
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.
Further Reading
- Five stocks we like better than Cosmo Pharmaceuticals
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 4/22 – 4/26
- Compound Interest and Why It Matters When Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are Dividend Achievers? An Introduction
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.